You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-1 Receptor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma (HCC) Trial in Nancy, Paris (Pexastimogene Devacirepvec (Pexa Vec), Nivolumab)

Terminated
Has Results
  • Hepatocellular Carcinoma (HCC)
  • Nancy, France
  • +1 more
Oct 21, 2021

Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in

Recruiting
  • Malignant Pleural Mesothelioma, Advanced
  • Oncolytic Adenovirus H101
  • Programmed death receptor-1 inhibitor
  • Tianjin, Tianjin, China
    Tianjin Medical Unversity Second Hospital
Sep 2, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

Breast Cancer Trial in Guangzhou (Chidamide Plus Toripalimab Plus Paclitaxel)

Recruiting
  • Breast Cancer
  • Chidamide Plus Toripalimab Plus Paclitaxel
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 19, 2023

Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V Trial in Beijing (KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +4 more
  • KRAS-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022

Solid Tumor, Adult, Lymphoma, EphA2 Overexpression Trial in Beijing (TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +6 more
  • TP53-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022

Breast Cancer Trial in Boston (Pembrolizumab, Nab-Paclitaxel, Biopsy)

Active, not recruiting
  • Breast Cancer
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Aug 22, 2022

B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

Active, not recruiting
  • B-cell Lymphoma
  • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022

Cancer Trial in United States (JTX-4014)

Active, not recruiting
  • Cancer
  • Denver, Colorado
  • +3 more
Sep 9, 2022

Head Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Oral Cavity Squamous Cell Carcinoma Trial in Nashville

Not yet recruiting
  • Head and Neck Cancer
  • +9 more
  • Nashville, Tennessee
    Vanderbilt-Ingram Cancer Center
Aug 9, 2022

Hepatocellular Carcinoma Trial in Beijing, Shanghai, Shenyang (SCG101, PD1/PD-L1 checkpoint inhibitor)

Recruiting
  • Hepatocellular Carcinoma
  • SCG101
  • PD1/PD-L1 checkpoint inhibitor
  • Beijing, China
  • +3 more
May 7, 2022

Castrate-Resistant Prostate Cancer Trial in Hangzhou (PD1-PSMA-CART cells)

Recruiting
  • Castrate-Resistant Prostate Cancer
  • PD1-PSMA-CART cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University
Feb 26, 2022

Advanced Breast Cancer Trial in Dallas (PD-0332991 and T-DM1)

Completed
  • Advanced Breast Cancer
  • PD-0332991 and T-DM1
  • Dallas, Texas
    UT Southwestern Medical Center
Jan 24, 2022

Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)

Recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 8, 2023

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

Recruiting
  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Nivolumab
  • Pembrolizumab
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022

Malignant Epithelial Tumors Trial in Portland (TCR-transduced T cells, CDX-1140, Pembrolizumab)

Not yet recruiting
  • Malignant Epithelial Neoplasms
  • TCR-transduced T cells
  • +2 more
  • Portland, Oregon
    Providence Portland Medical Center
Apr 22, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Tumor Trial in

Suspended
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
May 23, 2022

Metastatic Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7 Trial in United States (drug, other, biological)

Suspended
  • Metastatic Breast Carcinoma
  • Stage IV Breast Cancer AJCC v6 and v7
  • Corona, California
  • +6 more
Sep 28, 2022

Invasive Breast Cancer Trial in Milwaukee (Cemiplimab, Paclitaxel, Carboplatin (not mandatory))

Recruiting
  • Invasive Breast Cancer
  • Milwaukee, Wisconsin
    Froedtert Hospital & Medical College of Wisconsin
Apr 1, 2022

Rectal Cancer Trial in New York (Etrumadenant (AB928), Radiation therapy, FOLFOX regimen)

Recruiting
  • Rectal Cancer
  • Etrumadenant (AB928)
  • +3 more
  • New York, New York
  • +2 more
Apr 10, 2022

Relapsed/ Refractory Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, PD-1 Inhibitor)

Recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • Denver, Colorado
  • +19 more
Jan 27, 2023

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer, Head Cancer Trial in United States (IK-175 + nivolumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +5 more
  • IK-175 + nivolumab
  • Chicago, Illinois
  • +3 more
Jul 26, 2022

Ovarian Cancer Trial in United States (TPIV200, Durvalumab)

Completed
Has Results
  • Ovarian Cancer
  • TPIV200
  • Durvalumab
  • Basking Ridge, New Jersey
  • +4 more
Nov 1, 2021

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 Trial

Active, not recruiting
  • Anatomic Stage I Breast Cancer AJCC v8
  • +20 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 12, 2022

Urothelial Carcinoma, Triple Negative Breast Cancer, NSCLC Trial (SBT6290, pembrolizumab)

Withdrawn
  • Urothelial Carcinoma
  • +4 more
  • (no location specified)
Apr 4, 2022